2YR企业会员
| 英文名称 | 中文名称 | CAS |
|---|---|---|
| Ozoralizumab | Ozoralizumab | 1167985-17-2 |
| Drozitumab | DROZITUMAB ( 曲齐妥单抗 ) | 912628-39-8 |
| Roledumab | ROLEDUMAB ( 罗来度单抗 ) | 1174008-79-7 |
| Blosozumab | BLOSOZUMAB ( 布索组单抗 ) | 1132758-87-2 |
| Sirukumab | SIRUKUMAB ( 西鲁库单抗 ) | 1194585-53-9 |
| Enoticumab | Enoticumab | 1192578-27-0 |
| Ocaratuzumab | 奥卡妥珠单抗 | 1169956-08-4 |
| Bimagrumab | Bimagrumab | 1356922-05-8 |
| Lodelcizumab | Lodelcizumab | 1355338-54-3 |
| Bectumomab | 贝妥莫单抗 | 158318-63-9 |
| Secukinumab | 苏金单抗 | 1229022-83-6 |
| Rontalizumab | RONTALIZUMAB ( 隆利组单抗 ) | 948570-30-7 |
| Dalotuzumab | DALOTUZUMAB ( 达罗托组单抗 ) | 1005389-60-5 |
| Icrucumab | ICRUCUMAB ( 艾芦库单抗 ) | 1024603-92-6 |
| Tregalizumab | 曲利组单抗 | 1207446-68-1 |
| Flanvotumab | Flanvotumab | 1188277-05-5 |
| Clazakizumab | 克拉扎珠单抗 | 1236278-28-6 |
| Nesvacumab | 奈伐苏单抗 | 1296818-77-3 |
| Daratumumab | 达妥木单抗 | 945721-28-8 |
| Lirilumab | Lirilumab | 1000676-41-4 |
| Sifalimumab | SIFALIMUMAB ( 西法木单抗 ) | 1006877-41-3 |
| Enokizumab | ENOKIZUMAB ( 依诺凯组单抗 ) | 909875-08-7 |
| Onartuzumab | ONARTUZUMAB ( 奥那妥组单抗 ) | 1133766-06-9 |
| Indatuximab Ravtansine | Indatuximab Ravtansine | 1238517-16-2 |
| Quilizumab | Quilizumab | 1228538-47-3 |
| Placulumab | Placulumab | 945781-29-3 |
| Concizumab | Concizumab | 1312299-39-0 |
| Maslimomab | Masoprocol | 127757-92-0 |
| Minretumomab | 明瑞莫单抗 | 195189-17-4 |
| Samalizumab | Samalizumab | 1073059-33-2 |
| Pidilizumab | Pidilizumab | 1036730-42-3 |
| Vepalimomab | VEPALIMOMAB ( 维帕莫单抗 ) | 195158-85-1 |
| Ensituximab | ENSITUXIMAB ( 恩妥昔单抗 ) | 1092658-06-4 |
| Atinumab | ATINUMAB ( 阿替奴单抗 ) | 1226761-65-4 |
| Crenezumab | Crenezumab | 1095207-05-8 |
| Tabalumab | TABALUMAB ( 他贝芦单抗 ) | 1143503-67-6 |
| Fasinumab | 法司努单抗 | 1190239-42-9 |
| Orticumab | Orticumab | 1314241-10-5 |
| Pinatuzumab Vedotin | Pinatuzumab Vedotin | 1313706-14-7 |
| Zolimomabaritox | 阿佐莫单抗 | 141483-72-9 |
| Nerelimomab | Nerelimomab [usan:inn] | 162774-06-3 |
| Alirocumab | 阿利库单抗 | 1245916-14-6 |
| Rilotumumab | RILOTUMUMAB ( 利妥木单抗 ) | 872514-65-3 |
| Mavrilimumab | 玛弗利木单抗 | 1085337-57-0 |
| Olokizumab | OLOKIZUMAB ( 奥洛组单抗 ) | 1007223-17-7 |
| Ublituximab | UBLITUXIMAB ( 乌妥昔单抗 ) | 1174014-05-1 |
| Narnatumab | Narnatumab | 1188275-92-4 |
| Imgatuzumab | Imgatuzumab | 959963-46-3 |
| Ozanezumab | Ozanezumab | 1310680-64-8 |
| Pritoxaximab | Pritoxaximab | 1351470-16-0 |
| Lampalizumab | 兰帕利珠单抗 | 1278466-20-8 |
| Vedolizumab | 维多珠单抗 | 943609-66-3 |
| Romosozumab | ROMOSOZUMAB | 909395-70-6 |
| Mogamulizumab | Mogamulizumab | 1159266-37-1 |
| Benralizumab | BENRALIZUMAB | 1044511-01-4 |
| Fezakinumab | FEZAKINUMAB ( 非扎奴单抗 ) | 1007106-86-6 |
| Suvizumab | SUVIZUMAB ( 舒维组单抗 ) | 914257-21-9 |
| Etrolizumab | ETROLIZUMAB ( 依曲利组单抗 ) | 1044758-60-2 |
| Ponezumab | PONEZUMAB ( 泊奈组单抗 ) | 1178862-65-1 |
| Caplacizumab | 卡拉西单抗 | 915810-67-2 |
| Actoxumab | Actoxumab | 1245634-25-6 |
| Simtuzumab | 辛妥珠单抗 | 1318075-13-6 |
| Tildrakizumab | Tildrakizumab | 1326244-10-3 |
| Foralumab | FORALUMAB ( 福雷芦单抗 ) | 946415-64-1 |
| Carlumab | CARLUMAB ( 卡芦单抗 ) | 915404-94-3 |
| Ficlatuzumab | Ficlatuzumab | 1174900-84-5 |
| Vatelizumab | VATELIZUMAB ( 伐利组单抗 ) | 1238217-55-4 |
| Futuximab | Futuximab | 1310460-85-5 |
| Parsatuzumab | 帕萨妥珠单抗 | 1312797-14-0 |
| Solanezumab | 茄尼醇单抗 | 955085-14-0 |
| Evolocumab | 依洛尤单抗 | 1256937-27-5 |
| Patritumab | 帕曲妥单抗 | 1262787-83-6 |
| Rovelizumab | ROVELIZUMAB ( 罗维珠单抗 ) | 339086-79-2 |
| Teprotumumab | TEPROTUMUMAB ( 替妥木单抗 ) | 1036734-93-6 |
| Oxelumab | OXELUMAB ( 奥塞芦单抗 ) | 1186098-83-8 |
| Vesencumab | VESENCUMAB ( 维森库单抗 ) | 1205533-60-3 |
| Pateclizumab | 帕替组单抗 | 1202526-59-7 |
| Duligotuzumab | Duligotuzumab | 1314238-96-4 |
| Ligelizumab | Ligelizumab | 1322627-61-1 |
| Seribantumab | Seribantumab | 1334296-12-6 |
| Setoxaximab | Setoxaximab | 1351470-17-1 |
| Nacolomab Tafenatox | Nacolomabtafenatox | 150631-27-9 |
| Urelumab | 乌瑞芦单抗 | 934823-49-1 |
| Olaratumab | 奥拉单抗 | 1024603-93-7 |
| Lebrikizumab | 来瑞组单抗 | 953400-68-5 |
| Glembatumumab | GLEMBATUMUMAB ( 格巴妥木单抗 ) | 1020264-78-1 |
| Fulranumab | FULRANUMAB ( 福拉奴单抗 ) | 902141-80-4 |
| Radretumab | RADRETUMAB ( 雷曲妥单抗 ) | 1253180-81-2 |
| Bezlotoxumab | Bezlotoxumab | 1246264-45-8 |
| Vorsetuzumab | Vorsetuzumab | 1165740-62-4 |
| Dusigitumab | Dusigitumab | 1204390-13-5 |
| Itolizumab | 伊利组单抗 | 1116433-11-4 |
| Brodalumab | 布罗达单抗 | 1174395-19-7 |
| Intetumumab | INTETUMUMAB ( 英妥木单抗 ) | 725735-28-4 |
| Girentuximab | 吉妥昔单抗 | 916138-87-9 |
| Enavatuzumab | ENAVATUZUMAB ( 依那妥组单抗 ) | 1062149-33-0 |
| Namilumab | NAMILUMAB ( 那美芦单抗 ) | 1206681-39-1 |
| Solitomab | Solitomab | 1005198-65-1 |
| Perakizumab | 培拉凯珠单抗 | 1331830-76-2 |
| Modotuximab | Modotuximab | 1310460-86-6 |
联系方式
